DIM
PRVB

DC Investments Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

DC Investments Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-40,950
Closed -$164K – 330
2018
Q3 		$164K Buy
+40,950
New +$162K 0.11% 272

Other funds holding PRVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AIM
Alambic Investment Management Belvedere, California $9.12M AUM 34.55% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Cubist Systematic Strategies
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DC Investments Management's PRVB Position: Q4 2018 in Review

DC Investments Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2018, closing a stake of 40,950 shares — an estimated $164K sold.

DC Investments Management first reported a position in PRVB in Q3 2018 and held it in 1 quarter. The position peaked at $164K in Q3 2018. 11 funds tracked by Wall St. Rank hold PRVB as of Q4 2018.

  • DC Investments Management reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • DC Investments Management sold 40,950 Provention Bio, Inc. Common Stock shares in Q4 2018, an estimated $164K.
  • DC Investments Management first reported a position in Provention Bio, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • DC Investments Management's Provention Bio, Inc. Common Stock position peaked at $164K in Q3 2018.
  • 11 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2018.

Based on DC Investments Management's 13F filing for Q4 2018, filed 8 Feb 2019.